

<b>Curriculum Vitae</b>	Il sottoscritto (cognome e nome), ai sensi di quanto previsto dagli artt. 19, 46 e 47 del D.P.R. 445/2000, consapevole delle conseguenze derivanti in caso di rilascio di dichiarazioni false, dichiara sotto la propria responsabilità che tutte le eventuali fotocopie allegate alla domanda di partecipazione al concorso, sono conformi all'originale in suo possesso e che ogni dichiarazione resa risponde a verità
<b>Personal information</b>	
First name / Surname	<b>SALVATORE ANNUNZIATA</b>
Address	
Telephone	
E-mail	
Nationality	Italiana
Date of birth	
Gender	
<b>Education and training</b>	
Dates	September 2005 – October 2011
Title of qualification awarded	<b>Laurea in Medicina e Chirurgia</b>
Institution	Faculty of Medicine and Surgery Università Cattolica del Sacro Cuore – Roma, Italy
Dates	July 2012 – June 2017
Title of qualification awarded	<b>Specializzazione in Medicina Nucleare</b> Università Cattolica del Sacro Cuore – Policlinico "A. Gemelli" – Scuola di Specializzazione in Medicina Nucleare, Rome, Italy
Dates	November 2017- now
Title	<b>PhD – Dottorato di Ricerca in Scienze Oncologiche</b> Università Cattolica del Sacro Cuore, Rome, Italy Ricerca sulla Radiomica PET/CT nei linfomi
<b>Observerships</b>	
Dates	March 2016 – July 2016 Cristo Re Hospital, Rome, Italy - Unità di Medicina Nucleare Pratica nella Scintigrafia renale con diuretico
Dates	November 2016 Memorial Sloan Kettering Cancer Center, New York, USA Molecular Imaging and Therapy Service Observer in PET/CT and radionuclide therapy in oncology
Dates	December 2016 Ichan - Mount Sinai Hospital, New York, USA Nuclear Medicine Unit Observer in PET/CT and PET/MR in lymphoma
Mother tongue(s)	<b>Italian</b>
Other language(s)	<b>Good knowledge of English (writing, reading and speaking)</b>
<b>Work experience</b>	
Dates	September 2017 Collaboratore a Contratto. PET/CT nei linfomi dell'adulto. Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome
Dates	October 2017-now Libero Professionista – Cardiologia Nucleare Istituto Diagnostico Meduri, Reggio Calabria

	<p>June 2018-now          Libero professionista – PET/CT          IRCCS IFO IRE ISG, Roma</p>
<b>Scientific Associations</b>	<p>Ordinary member of the Italian Association of Nuclear Medicine (AIMN),          European Association of Nuclear Medicine (EANM),          Society of Nuclear Medicine and Molecular Imaging (SNMMI)</p>
<b>Congress participations</b>	<p>AIMN 2015 and 2017 (Rimini), SNMMI 2016 (San Diego),          EANM 2014 and 2017 (Gothenburg and Vienna),          International Workshop on PET in Lymphoma 2014 and 2016 (Menton),          European Congress of Cardio-Thoracic Surgery 2016 (Barcelona),          Clinical Trial Center Course – Gemelli Hospital (2015),          Next Clinical Leaders Humanitas-Bocconi (Milano 2016),          Workshop sulla Formazione Medica Specialistica (Genova 2017-2018).</p>
<b>Scientific interest fields</b>	<p>PET/CT – Oncology – Radionuclide therapy – Lymphoma - PET/MR          Publication ethics — Personalized medicine – Medical education</p>
<b>Scientific protocols</b>	<ul style="list-style-type: none"> <li>• Utilizzo della PET/CT con <math>^{64}\text{CuCl}_2</math> nei pazienti con recidiva biochimica di tumore prostatico da trattare con radioterapia</li> <li>• A Randomized, Open-Label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma.</li> <li>• EuroNET PHL C2. International Inter-group study on Classical Hodgkin Lymphoma in Children and Adolescents.</li> <li>• The predictive value of microRNAs (miRNAs) in the assessment of response to radioiodine therapy (RAI) in patients with differentiated thyroid carcinoma.</li> </ul>
<b>Grants and calls</b>	<ul style="list-style-type: none"> <li>• AIFA call 2018. Off-label use of propranolol to reduce brown adipose tissue activation in paediatric oncological patients undergoing <math>^{18}\text{F}</math>-FDG PET/CT.</li> <li>• PRIN call 2018. Characterization of Adrenal Tumors using Quantitative Parameters extracted by Diagnostic Imaging modalities.</li> <li>• IBSA fellowship 2018. New PET features in primary cutaneous lymphoma: from volumes to radiomics</li> <li>• SNMMI grant 2018. New FDG-PET/CT features in prognostic stratification of high-grade lymphoma: from volumes to radiomics</li> </ul>
<b>Prizes</b>	
<p>Date          Name          Title of work          Qualification</p>	<p>July 2014          EANM 2014 Young Investigator Meeting  <i>The predictive value of microRNAs (miRNAs) in the assessment of response to radioiodine therapy (RAI) in patients with differentiated thyroid carcinoma</i>          Candidate</p>
<p>Date          Name          Title of work          Qualification</p>	<p>July 2016          EANM 2016 Young Investigator Meeting  <i>xSPECT analysis in patients with Paget disease of the bone</i>          Candidate</p>
<b>Other activities</b>	<p>Reviewer for JNM and EJNMMI, Frontiers, PLOS-ONE          Webinar for EANM-ESMIT          Member of Organizing Committee of AIMN Congress Rimini 2017          Editorial Staff AIMN-Info newsletter, Young AIMN Committee</p>

**Scientific publications**  
(h-index 8 Scopus)

Original papers

- *Annunziata S, Cuccaro A, Tisi MC, Hohaus S, Rufini V.* FDG-PET/CT at the end of immuno-chemotherapy in Follicular Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). *Ann Nucl Med.* 2018 Jun;32(5):372-377.
- *Annunziata S, Cuccaro A, Calcagni ML, Indovina L, Hohaus S, Giordano A, Rufini V.* Interim FDG-PET/CT in patients with Hodgkin Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). *Ann Nucl Med.* 2016 Oct;30(8):588-92.
- Spina V, Brusca A, Cuccaro A, *Annunziata S*, Rossi D et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. *Blood.* 2018 May 31;131(22):2413-2425.
- Evangelista L, Cuocolo A, Pace L, Mansi L, ..., *Annunziata S*, Farsad M, Chiaravalloti A, Spadafora M. Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. *Eur J Nucl Med Mol Imaging.* 2018 Oct;45(11):1898-1907
- Cuccaro A, *Annunziata S*, Cupelli E, Martini M, Calcagni ML, Rufini V, Giachella M, Bartolomei F, Galli E, D'Alò F, Voso MT, Leone G, Alessandro A, Larocca L, Hohaus S. CD68+ Cell Count, Early Evaluation with PET and Plasma TARCC Levels Predict Response in Hodgkin Lymphoma. *Cancer Med.* 2016 Mar;5(3):398-406.
- Pizzuto DA, *Annunziata S*, Ierici FP, Caldarella C, Isgrò MA, Lanni V, Bencivenga G, Rufini V, Giordano A. Lung uptake of fluorine-18 fluorodeoxyglucose PET-CT in patients with prostate cancer. *Q J Nucl Med Mol Imaging.* 2018 Jan 17.

Case reports

- *Annunziata S, Cuccaro A, Rizzo A, Chiesa S, D'Alò F.* Bronchial Mucosa-Associated Lymphoid Tissue Lymphoma Staged by 11C-Methionine. *Clin Nucl Med.* 2018 Aug;43(8):e276-e277
- *Annunziata S, Cuccaro A, Caldarella C, Leccisotti L, Hohaus S.* 11C-Methionine-Avid Plasmablastic Lymphoma. *Clin Nucl Med.* 2017 Nov;42(11):872-873.
- *Annunziata S.* A rare case of 18F-FDG avid cardiac synovial sarcoma. *Rev Esp Med Nucl Imagen Mol.* 2018 Sep-Oct;37(5):322
- *Annunziata S, Cuccaro A, Caldarella C, Hohaus S.* Dural MALT lymphoma detected by 11C-Methionine PET/CT. *Clin Nucl Med.* 2017 Dec;42(12):962-963.
- *Annunziata S, Caldarella C.* A rare case of dorsal-cervical spine myeloid sarcoma detected on 18F-FDG PET/CT. *Rev Esp Med Nucl Imagen Mol.* 2017 Mar-Apr;36(2):127-128.
- Caldarella C, *Annunziata S*, Pagano L, De Stefano V, Rufini V. Improved detection of minimal residual disease by Carbon-11-Methionine PET/CT in a young patient with unusual extramedullary presentation of recurrent multiple myeloma. *Clin Nucl Med Clin Nucl Med.* 2017 Feb;42(2):e130-e134
- Rizzo A, Zagarra L, Perotti G, *Annunziata S*, Salvalori M, Salvalori M. Accumulation of 131I in Esophageal Diverticulum Diagnosed by SPECT/CT. *Clin Nucl Med.* 2018 Aug 31

Commentary

- *Annunziata S, Calcagni ML, Indovina L, Rufini V.* Measurement uncertainty and clinical impact of rPET and qPET in Hodgkin Lymphoma: reply to Laffon and Marthan. *Eur J Nucl Med Mol Imaging.* 2017 Nov;44(12):2140-2141.
- *Annunziata S, Giordano A.* Authorship problems in scientific literature and in nuclear medicine: the point of view of the young researcher. *Eur J Nucl Med Mol Imaging.* 2014 Jun;41(6):1251-4.
- Treglia G, *Annunziata S*, Muoio B, Salvalori M, Ceriani L, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. *Int J Endocrinol.* 2013;2013:856189.

Reviews

- *Annunziata S, Caldarella C, Treglia G.* Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review. *World J Radiol.* 2014 Mar 28;6(3):48-55.
- *Annunziata S, Treglia G, Caldarella C and Galiandro F.* The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review. *ScientificWorldJournal.* 2014 Feb 2;2014:879469. doi:10.1155/2014/879469.
- Treglia G, *Annunziata S*, Sobie Saranovic D, Bertagna F, Caldarella C, Ceriani L, Giovanella L. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. *Acad Radiol.* 2014 May;21(5):675-84.

Meta-analyses

- *Annunziata S, Pizzuto DA, Caldarella C, Galiandro F, Sadeghi R, Treglia G.* Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: A meta-analysis. *World J Gastroenterol.* 2015 Oct 28;21(40):11481-8.
- *Annunziata S, Caldarella C, Pizzuto DA, Galiandro F, Sadeghi R, Giovanella L, Treglia G.* Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in the evaluation of the primary tumor in patients with cholangiocarcinoma: a meta-analysis. *Biomed Res Int.* 2014;2014:247693.
- Treglia G, Sadeghi R, *Annunziata S*, Lococo F, Cafarotti S, Bertagna F, Prior JO, Ceriani L, Giovanella L. Diagnostic Accuracy of (18)F-FDG-PET and PET/CT in the Differential Diagnosis between Malignant and Benign Pleural Lesions: A Systematic Review and Meta-Analysis. *Acad Radiol.* 2014 Jan;21(1):11-20.
- Treglia G, Sadeghi R, *Annunziata S*, Lococo F, Cafarotti S, Prior JO, Bertagna F, Ceriani L, Giovanella L. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography in the assessment of pleural abnormalities in cancer patients: A systematic review and a meta-analysis. *Lung Cancer.* 2014 Jan;83(1):1-7.
- Treglia G, Sadeghi R, *Annunziata S*, Zakavi SR, Caldarella C, Muoio B, Bertagna F, Ceriani L, Giovanella L. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis. *Foot (Edinb).* 2013 Dec;23(4):140-8.
- Caldarella C, *Annunziata S*, Treglia G, Sadeghi R, Ayati N, Giovanella L. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting loco-regional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. *ScientificWorldJournal.* 2014 Feb 4;2014:196068. doi: 10.1155/2014/196068.
- Treglia G, Sadeghi R, *Annunziata S*, Caldarella C, Bertagna F, Giovanella L. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis. *Biomed Res Int.* 2014;2014:852681.

## Main Congress Abstracts

- Annunziata S, Pelliccioni A, Maiolo E, Cuccaro A, Hohaus S, Giordano A. Neural Networks improves the prognostic value of end-of-treatment FDG-PET/CT in diffuse large B-cell lymphoma. EANM Dusseldorf 2018
- Annunziata S, Cuccaro A, Hohaus S, Maiolo E, Rufini V. The prognostic role of semi-quantitative parameters by FDG-PET/CT in Large B cell Lymphoma at the end of chemo-immunotherapy (DLBCL). SNMMI Philadelphia 2018
- Annunziata S, Cuccaro A, Tisi MC, Hohaus S, Rufini V. FDG-PET/CT at the end of immuno-chemotherapy in Follicular Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). EANM Vienna 2017
- Cuccaro A, Zangrilli I, Corrente F, Cupelli E, Fatone F, Galli E, Annunziata S, Rufini V, Balducci M, D'Alò F, Bellesi S, De Stefano S, Hohaus S. The neutrophil PD-L1 and lymphocyte PD-1 axis in the peripheral blood in classical Hodgkin lymphoma. SIES 2018
- Maiolo M, D'Alò F, Bellesi A, Cuccaro A, Alma E, Rufini V, Leccisotti L, Annunziata S, Rizzo A, Macis G, Calandriello L, Balducci M, Chiesa S, De Stefano V, Hohaus S. THE PROGNOSTIC ROLE OF 18FDG-PET/TAC AT THE END OF FIRST LINE CHEMO-IMMUNOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: A MONOCENTRIC STUDY ON 308 PATIENTS. EHA 2018
- Annunziata S, Cuccaro A, Hohaus S, Rufini V. Interim FDG-PET/CT in patients with Hodgkin Lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). SNMMI San Diego 2016
- Annunziata S, Cuccaro A, Hohaus S, Rufini V. Interim FDG-PET/CT in Hodgkin Lymphoma: the prognostic value of ratios between target lesion and background SUV. AIMN Rimini 2017
- Annunziata S, Tisi MC, Miglietta G, Hohaus S, Rufini V. The prognostic role of FDG-PET/CT at the end of induction immunochemotherapy (PI-PET) in patients with Follicular Lymphoma: a retrospective monocentric study. SNMMI San Diego 2016.
- Annunziata S, Cuccaro A, Rufini V, Calcagni M, Giachelia M, Martini M, D'Alò F, Larocca L, Hohaus S, Giordano A. The prognostic role of interim FDG-PET/CT, CD68+ cells count and levels of plasma Thymus and Activation-Regulated Chemokine in the treatment of Hodgkin Lymphoma. AIMN Congress, Rimini 2015. Clin Transl Imaging (2015) 3 (Suppl 1):S1-S144
- Annunziata S, Calcagni M, Rufini V, Cuccaro A, Massini G, Bartolomei F, Giachelia M, Cenci T, Martini M, D'Alò F, Leone G, Larocca L, Hohaus S, Giordano A. The prognostic role of interim FDG-PET/CT and CD68+ cells count in the treatment of Hodgkin Lymphoma. EANM Gothenburg 2014. Eur J Nucl Med Mol Imaging (2014) 41 (Suppl 2):S151-S705
- C. Caldarella, Annunziata S, M. Isgro, A. Giordano. Carbon-11-Methionine PET/CT derived functional parameters in patients with primary hyperparathyroidism reflect PTH-secretory activity of parathyroid glands: a retrospective single-centre evaluation. EANM Barcelona 2016.
- M. Lavalle, V. Alberti, Annunziata S, L. Leccisotti, M. Orrico, S. Ronchey, N. Mangialardi, A. Giordano. The role of 18F-FDG PET/CT in the diagnosis and response to medical treatment of inflammatory aneurysms of abdominal aorta. A prospective pilot study. EANM Barcelona 2016 and AIMN Rimini 2017
- Pizzuto DA, Annunziata S, Brunelli C, Perotti G, Rossi ED, Martini M, Larocca LM, Salvatori M, Fadda G. The predictive value of post-operative bRAF analysis in patients with differentiated thyroid cancer submitted to radioiodine treatment. Clin Transl Imaging (2015) 3 (Suppl 1):S1-S144
- Pizzuto DA, Caldarella C, Annunziata S, Ieria FP, Isgro MA, Rufini V, Giordano A. Incidental lung uptake of Fluorine-18 FluoroCholine PET-CT in patients with recurrent prostate cancer: a first retrospective analysis. EANM Congress, Hamburg 2015.
- Tartaglione G, Foschi N, Annunziata S, Gandi C, Bassi P. Gravity Assisted Diuretic Renography for evaluation of Uretero-Ileal Anastomosis in Bladder Cancer Patients. SNMMI San Diego 2017 and AIMN Rimini 2017.
- Spadafora M, Mansi L, Cuocolo A, Evangelista L, Guerra L, Fanti S, Nicolai E, A Chiti, Zuffante, Schillaci O, Del Vecchio S, Peluso G, Annunziata S, Fracchetti A, Ripani D, Gridelli C, Miletto P, Pace L. Segmental FDG-PET/CT in solitary pulmonary nodule: preliminary data of the PET ITALIAN trial. AIMN Rimini 2017, SNMMI Denver 2017 and EANM Vienna 2017.

## Ongoing Studies

- Valutazione mediante Reti Neurali della PET di fine trattamento dei Linfomi ad alto grado
- Ruolo diagnostico della PET-TC con 18F-FDG nel linfoma di Hodgkin multiresistente in trattamento con Nivolumab
- Valutazione dell'impatto clinico del tumor board ospedaliero nel management dei pazienti con Linfoma
- Nuovi metodi didattici e curriculum delle Scuole di Specializzazione mediche
- Nuovi parametri di Radiomica nella stadiazione del linfoma di Hodgkin
- Ruolo della PET-TC nella definizione dei volumi target per la radioterapia
- Clinical Value of PET/CT at Staging and potential new radiotracers in melanoma

Roma 01/11/2018

Allegato 2

**MODELLO DICHIARAZIONI COLLABORATORI, PROFESSIONISTI E CONSULENTI**

Il/la sottoscritto/a ANNUNZIATA SALVATORE CI: NNN SUT 86 RIO FP3R IS  
nato/a il 10/10/1986, residente in ROMA, VIA LUIGI ARBIB PADUCCCI 64 - 00168  
in relazione all'incarico di LAVORO AUTONOMO PER L'EROGAZIONE DI PRESTAZIONI NELLA  
DISCIPLINA DI MEDICINA NUCLEARE da stipularsi con gli IFO consapevole delle sanzioni penali, nel  
caso di dichiarazioni non veritiere e falsità negli atti, richiamate dall'art. 76 del DPR n. 445/2000

**DICHIARAZIONE DI INCONFERIBILITA'/INCOMPATIBILITA'**

Dichiaro:

- di non ricadere in alcuna delle cause di inconferibilità previste dal D.Lgs. 39/2013 ed in particolare in quelle di cui all'art. 3 (inconferibilità di incarichi in caso di condanna per reati contro la pubblica amministrazione), all'art. 4 (inconferibilità di incarichi nelle amministrazioni statali);
- di non ricadere in alcuna delle cause di inconferibilità di cui all'art. 20, comma 5, D.Lgs. 39/2013 per aver rilasciato dichiarazioni sostitutive mendaci;

**DICHIARAZIONE INCARICHI/CARICHE RICOPERTE ED ATTIVITÀ PROFESSIONALI**

Dichiaro ai sensi dell'art. 15, commi 1 e 2 del D.Lgs. 33/2013:

- di:  
 non ricoprire  
 ricoprire le seguenti cariche o incarichi presso enti di diritto privato regolati o finanziati dalla pubblica amministrazione:

Carica/Incarico	Ente	Periodo (data inizio/cessazione)	Compensi a qualsiasi titolo corrisposti

- di:  
 non svolgere  
 svolgere le seguenti attività professionali

• DOTTORATO DI RICERCA IN ONCOLOGIA - UNIVERSITA' CATTOLICA SACRO CUORE  
• CARDIOLOGIA NUCLEARE - LIBERA PROFESSIONE - ISTITUTO PRIVATO MEDURI - RC

**ULTERIORI DICHIARAZIONI**

Dichiaro infine:

- di non trovarmi allo stato in situazioni, anche potenziali, di conflitto di interesse con l'attività svolta, e di impegnarmi a rendere annualmente una analoga dichiarazione ai sensi dell'art. 20, co. 2, D.Lgs. 39/2013, e a comunicare tempestivamente eventuali variazioni del contenuto della presente dichiarazione;
- di essere a conoscenza di quanto previsto dalla Legge 190/2012 e dal Piano Triennale di Prevenzione della Corruzione degli IFO, condividendo e osservandone i principi generali e i protocolli specifici.

Ai sensi di quanto previsto dal D.Lgs. 196/2003, con la sottoscrizione, presto il consenso alla pubblicazione della presente dichiarazione in apposita sezione del sito istituzionale degli IFO

Luogo, ROMA

Data, 1/11/2018